BIOMAT Database Logo BIOMAT Database Logo

Hepatitis B virus surface antigen and anti-hepatitis C virus rapid tests underestimate hepatitis prevalence among HIV-infected patients. 2014

Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
The Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

OBJECTIVE In the case of coinfection with HIV and hepatitis B virus (HBV) and/or hepatitis C virus (HCV), hepatic disease progression is often accelerated, with higher rates of liver cirrhosis and liver-related mortality. We aimed to evaluate the performance of the rapid tests used routinely to detect HBV surface antigen (HBsAg) and anti-HCV among HIV-infected patients in Guinea-Bissau. METHODS Blood samples from HIV-infected patients in Guinea-Bissau were stored after testing for HBsAg and anti-HCV with rapid tests. Samples were subsequently re-tested for HBsAg and anti-HCV in Denmark. RESULTS Two rapid tests were used in Guinea-Bissau: HBsAg Strip Ref 2034 (VEDA.LAB, Alençon, France; sensitivity 62.3%; specificity 99.2%) and HEPA-SCAN (Bhat Bio-Tech, Bangalore, India; sensitivity 57.1%; specificity 99.7%). In the two tests the ability to obtain the correct outcome depended on the antigen and antibody concentrations, respectively. Sex, age, CD4 cell count and antiretroviral therapy status did not differ between false negative and true positive samples in either of the tests. The study is limited by a low number of anti-HCV positive samples. CONCLUSIONS New diagnostic rapid tests should always be evaluated in the setting in which they will be used before implementation.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D006169 Guinea-Bissau A republic in western Africa, south of SENEGAL and west of GUINEA. Its capital is Bissau. Guinea, Portuguese,Portuguese Guinea,Guinea-Bissau, Republic of,Republic of Guinea-Bissau
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences

Related Publications

Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
Prevalence of hepatitis C virus among HIV-infected patients.
April 2020, Iranian journal of microbiology,
Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
Seroprevalence of anti-HCV and hepatitis B surface antigen in HIV infected patients.
January 2003, Indian journal of medical microbiology,
Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
Comparative study of serum and salivary hepatitis B surface antigen and hepatitis C antibodies among patients infected with hepatitis B or C virus.
July 1995, Egyptian dental journal,
Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
Serological pattern 'anti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants.
February 2004, AIDS (London, England),
Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.
October 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
Prevalence of hepatitis B surface antigen seropositivity among HIV-infected and non-infected individuals in Nnewi, Nigeria.
October 2012, Nigerian medical journal : journal of the Nigeria Medical Association,
Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
Comparison of hepatitis B surface antigen, anti-hepatitis B surface, and anti-hepatitis C virus prevalence in Syrian refugee pregnant women and Turkish pregnant women.
January 2023, Revista da Associacao Medica Brasileira (1992),
Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria.
February 2005, Memorias do Instituto Oswaldo Cruz,
Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
Hepatitis B surface antigen and antibody to hepatitis C virus among accident and emergency patients.
September 2001, East African medical journal,
Bl Hønge, and S Jespersen, and C Medina, and Ds Té, and Zj da Silva, and L Ostergaard, and Al Laursen, and C Wejse, and H Krarup, and C Erikstrup, and
Prevalence of hepatitis B surface antigen and hepatitis C virus antibodies among blood donors in Alexandria, Egypt.
March 2011, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit,
Copied contents to your clipboard!